Investigation Report on China’s Nicergoline Markets, 2016-2020 & 2021-2025: A Kind of Ergot Derivative, Used to Treat Alzheimer’s Disease and Other Vascular Diseases, Originally Researched by Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Nicergoline Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Nicergoline is a kind of ergot derivative, used to treat Alzheimer’s disease and other vascular diseases, originally researched by Pfizer Pharmaceuticals.

Since its successful development in the 1960s, it has been registered and used in more than 50 countries. By 2020, Nicergoline has been included in China’s Class B medical insurance, and there are already several manufacturers in the Chinese market, among which Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd. has the most market share.

According to the analyst’s market research, the sales value of Nicergoline in the Chinese market has increased year by year from 2016 to 2020. Among them, the growth in 2019 was the most obvious.

The sales value of Nicergoline increased from CNY138 million in 2018 to CNY190 million in 2019, with an annual growth rate of 37.57%. In 2020, the sales value of Nicergoline in the Chinese market is CNY237 million, and the CAGR from 2016 to 2020 is 16.6%.

The analyst expects that with the increase in the number of patients with Alzheimer’s disease, the sales value of Nicergoline in the Chinese market will continue to grow from 2021 to 2025.

By 2020, the incidence of Alzheimer’s disease in the elderly over 65 years old in China was 4%-6%, and the aging degree in China will continue to increase in the future, which will cause the number of patients with Alzheimer’s disease to continue to increase. Therefore, sales volume and sales value in Nicergoline will also continue to increase.

Topics Covered:

• The impact of COVID-19 on China’s Nicergoline market
• Sales value of China’s Nicergoline 2016-2020
• Competitive landscape of China’s Nicergoline market
• Prices of Nicergoline in China
• Prices of Nicergoline in China by regions and manufacturers
• Analysis on factors affecting the development of China’s Nicergoline market
• Prospect of China’s Nicergoline market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Nicergoline

1.1 Indications for Nicergoline

1.2 Development of Nicergoline in China

1.3 Governmental Approval of Nicergoline in China

1.4 The Impact of COVID-19 on Nicergoline sales in China

2 Sales of Nicergoline in China, 2016-2020

2.1 Sales Value of Nicergoline

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Nicergoline

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Nicergoline by Dosage Form in China, 2016-2020

2.3.1 Tablets

2.3.2 Injection

2.3.3 Capsules

3 Analysis of Major Nicergoline Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Nicergoline Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of Lexilin (Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd.’s Nicergoline) in China

3.3 Hainan General Kangli Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Hainan Puli (Hainan General Kangli Pharmaceutical Co., Ltd. ‘s Nicergoline) in China

3.4 Pfizer Pharmaceuticals Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of SERMION (Pfizer Pharmaceuticals Co., Ltd.’s Nicergoline) in China

3.5 Chengdu Tiantaishan Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Fulutong (Chengdu Tiantaishan Pharmaceutical Co., Ltd.’s Nicergoline) in China

3.6 Hainan general Sanyo Pharmaceutical Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Kaier (Hainan general Sanyo Pharmaceutical Co., Ltd.’s Nicergoline) in China

4 Prices of Nicergoline for Different Manufacturers in China, 2020-2021

4.1 Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd. (Lexilin)

4.2 Hainan General Kangli Pharmaceutical Co., Ltd. (Hainan Puli)

4.3 Pfizer Pharmaceuticals Co., Ltd. (SERMION)

4.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd. (Fulutong)

4.5 Hainan general Sanyo Pharmaceutical Co., Ltd. (Kaier)

5 Prospect of Chinese Nicergoline Market, 2021-2025

5.1 Influential Factors of Chinese Nicergoline Market Development

5.1.1 The Impact of COVID-19 on Chinese Nicergoline Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/38mdso

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900